WEBULL
WebtradeDownload

3 European Dividend Stocks For Steady Income As Bond Yields Rise

Simply Wall St · 1d ago

Surging long term U.S. Treasury yields are shaking global markets and pulling European equities into the crossfire, which puts a fresh spotlight on steady, cash rich dividend stocks. When bond volatility rattles confidence, investors often pay closer attention to reliable income and resilient balance sheets, and those can be harder to find than headlines suggest. This article walks through three stocks from our European high dividend, defensive value screener that appear particularly exposed to the current interest rate shock and sets out why each one may deserve a closer look right now.

The stocks covered below are just a starting sample from this theme, and the full screen surfaced 13 more European high dividend, defensive companies with equally compelling income and value stories that are not discussed here. If you want to identify and analyze potential higher conviction ideas right now, head straight to the European High-Dividend, Defensive Value Stocks screener.

Siemens Healthineers (XTRA:SHL)

Overview: Siemens Healthineers is a large European healthcare equipment and services company that supplies hospitals and clinics worldwide with imaging systems, diagnostic tests, cancer treatment technology and minimally invasive therapy tools, often under long running service and support contracts. This steady demand for essential medical infrastructure ties it closely to the defensive, dividend focused healthcare theme of the screener.

Operations: Siemens Healthineers generates most of its revenue from Imaging at about €13.2b, with Diagnostics contributing around €4.1b, supported by additional segment adjustments and group level reconciliations.

Market Cap: €44.7b

For investors looking for resilience while bond yields keep climbing, Siemens Healthineers offers a mix of essential hospital equipment, recurring service contracts and a history of solid margins that support its dividend profile. The stock screens as a value oriented healthcare player, with analysts highlighting cash generation from imaging and therapy systems and growing AI based software as key drivers for steadier earnings. The flip side is meaningful debt on the balance sheet and ongoing pressure in Diagnostics and China that could matter more as interest costs rise. With leadership changes in the Americas and continued investment in advanced cancer care platforms, the full story on risk, income potential and valuation is more nuanced than the headline label of a defensive healthcare stock suggests.

Siemens Healthineers’ mix of cash rich imaging, therapy platforms and AI software often gets reduced to a simple “defensive” label, yet the real trade off between income, valuation and balance sheet risk only shows up in the 4 key rewards and 1 important warning sign

XTRA:SHL Revenue & Expenses Breakdown as at Aug 2026
XTRA:SHL Revenue & Expenses Breakdown as at Aug 2026

Build your own defensive dividend shortlist

Siemens Healthineers and the other two stocks in this list were all found using a simple screener, which you can easily adapt to your own style. Use our flexible Screener to mix filters like valuation, dividends, balance sheet strength and risks into your own shortlist, or jump straight into any of our curated Investing Ideas.

Fresenius Medical Care (XTRA:FME)

Overview: Fresenius Medical Care runs one of the world’s largest dialysis networks, treating chronic kidney patients in clinics and at home, and also supplies the machines, consumables and medicines that keep those treatments running. That mix of non discretionary, recurring care and an established dividend record is why it features in a European high dividend, defensive healthcare screen.

Operations: Fresenius Medical Care generates most of its revenue from Care Delivery at about €13.7b, with a further €5.4b from Care Enablement and €2.2b from Value Based Care, partially offset by inter segment eliminations and supported by substantial exposure to the United States at around €14.1b in sales.

Market Cap: €10.6b

Fresenius Medical Care offers investors a mix of defensive dialysis cash flows, a roughly 3.7% dividend yield and a share price that screens as heavily discounted relative to long term cash flow estimates. This combination is relatively uncommon when bond yields are punishing more cyclical sectors. The company is working on margin uplift through its FME25+ efficiency program, higher value care models and the rollout of its 5008X dialysis platform, while also returning excess cash through sizeable buybacks. The trade off is meaningful leverage, governance turnover and pressure points in U.S. referral trends and value based care profitability. For readers assessing whether that risk reward balance suits a conservative, income focused portfolio, the full story on Fresenius Medical Care extends well beyond these headlines.

Fresenius Medical Care’s discounted share price and dialysis cash flows could be masking a sharper earnings reset than many investors realise. Get the full context in the 5 key rewards and 1 important warning sign

XTRA:FME Revenue & Expenses Breakdown as at Aug 2026
XTRA:FME Revenue & Expenses Breakdown as at Aug 2026

Danone (ENXTPA:BN)

Overview: Danone is a large European food and beverage company that sells everyday consumer staples like yogurts, plant based products, baby formula, medical nutrition and bottled water across Europe, the Americas, Asia, the Middle East and Africa. This aligns it naturally with a defensive, dividend focused consumer staples theme.

Operations: Danone generates most of its revenue from Essential Dairy and Plant Based Products at about €13.2b, with around €9.4b from Specialized Nutrition and €4.9b from Waters.

Market Cap: €42.7b

Danone provides exposure to a broad portfolio of everyday nutrition and hydration brands that are often viewed as relatively resilient during unsettled markets. The company has a long history in consumer staples and a dividend yield around 3.39% that may appeal to income focused portfolios while bond yields remain elevated. Recent moves into health and medical nutrition, including acquisitions in gut health and plant based products, are intended to support earnings resilience. H1 2026 results showed like for like sales growth and recurring operating income growth that outpaced sales. The trade off is a relatively high debt load and ongoing work to improve performance in legacy dairy and North American businesses, which could be more significant if interest costs stay higher and competition in core categories remains intense.

Danone’s push into health focused nutrition and plant based products could be masking a deeper shift in how its earnings hold up through the cycle. Sense check that story against the analyst forecasts for Danone

ENXTPA:BN Revenue & Expenses Breakdown as at Aug 2026
ENXTPA:BN Revenue & Expenses Breakdown as at Aug 2026

Seeking Alternatives Before The Crowd Moves

Fresh ideas do not stay under the radar for long. While momentum builds and prices start flying, you may want to be early instead of reacting after the move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.